Skip Navigation

JNCI Journal of the National Cancer Institute 2001 93(19):1440-1441; doi:10.1093/jnci/93.19.1440
© 2001 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Randal, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Randal, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 93, No. 19, 1440-1441, October 3, 2001
© 2001 Oxford University Press

NEWS

Examining IRBs: Are Review Boards Fulfilling Their Duties?

Judith Randal

This is an introductory article to an occasional series that will take a close look at the clinical trials system.

If U.S. taxpayers are to foot the bill for a biomedical experiment on people, the protocol for the study—its research plan—must first satisfy an institutional review board that it provides for the informed consent of the participants and sufficient safeguards of their welfare.

Composed primarily of scientists and physicians, these watchdog panels are also responsible for checking, at least once a year, on the compliance with these requirements of any study they approve.

It has been that way since 1974 when Congress imposed reforms in response to then recent revelations of ethically flawed human experiments. A federally funded study during the 1960s in which live cancer cells were injected into debilitated noncancer patients . . . [Full Text of this Article]

‘Just Overwhelmed’

Adding IRBs

Financial Implications

Signs of Innovation

Accreditation Organization


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 JNCI J Natl Cancer InstHome page
Resources
J Natl Cancer Inst, May 7, 2003; 95(9): 637 - 637.
[Full Text]

Home page
 JAMAHome page
N. S. Sung, W. F. Crowley Jr, M. Genel, P. Salber, L. Sandy, L. M. Sherwood, S. B. Johnson, V. Catanese, H. Tilson, K. Getz, et al.
Central Challenges Facing the National Clinical Research Enterprise
JAMA, March 12, 2003; 289(10): 1278 - 1287.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
M. C. Christian, J. L. Goldberg, J. Killen, J. S. Abrams, M. S. McCabe, J. K. Mauer, and R. E. Wittes
A Central Institutional Review Board for Multi-Institutional Trials
N. Engl. J. Med., May 2, 2002; 346(18): 1405 - 1408.
[Full Text] [PDF]